132 related articles for article (PubMed ID: 35536872)
1. Bimodal Gene Expression in Patients with Cancer Provides Interpretable Biomarkers for Drug Sensitivity.
Ba-Alawi W; Nair SK; Li B; Mammoliti A; Smirnov P; Mer AS; Penn LZ; Haibe-Kains B
Cancer Res; 2022 Jul; 82(13):2378-2387. PubMed ID: 35536872
[TBL] [Abstract][Full Text] [Related]
2. Comparison and validation of genomic predictors for anticancer drug sensitivity.
Papillon-Cavanagh S; De Jay N; Hachem N; Olsen C; Bontempi G; Aerts HJ; Quackenbush J; Haibe-Kains B
J Am Med Inform Assoc; 2013; 20(4):597-602. PubMed ID: 23355484
[TBL] [Abstract][Full Text] [Related]
3. Gene isoforms as expression-based biomarkers predictive of drug response in vitro.
Safikhani Z; Smirnov P; Thu KL; Silvester J; El-Hachem N; Quevedo R; Lupien M; Mak TW; Cescon D; Haibe-Kains B
Nat Commun; 2017 Oct; 8(1):1126. PubMed ID: 29066719
[TBL] [Abstract][Full Text] [Related]
4. Systematic assessment of analytical methods for drug sensitivity prediction from cancer cell line data.
Jang IS; Neto EC; Guinney J; Friend SH; Margolin AA
Pac Symp Biocomput; 2014; ():63-74. PubMed ID: 24297534
[TBL] [Abstract][Full Text] [Related]
5. Beyond the limitation of targeted therapy: Improve the application of targeted drugs combining genomic data with machine learning.
Miao R; Chen HH; Dang Q; Xia LY; Yang ZY; He MF; Hao ZF; Liang Y
Pharmacol Res; 2020 Sep; 159():104932. PubMed ID: 32473309
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenomic biomarkers for personalized cancer treatment.
Rodríguez-Antona C; Taron M
J Intern Med; 2015 Feb; 277(2):201-217. PubMed ID: 25338550
[TBL] [Abstract][Full Text] [Related]
7. Bimodal gene expression and biomarker discovery.
Ertel A
Cancer Inform; 2010 Feb; 9():11-4. PubMed ID: 20234772
[TBL] [Abstract][Full Text] [Related]
8. Predicting Cancer Drug Response using a Recommender System.
Suphavilai C; Bertrand D; Nagarajan N
Bioinformatics; 2018 Nov; 34(22):3907-3914. PubMed ID: 29868820
[TBL] [Abstract][Full Text] [Related]
9. Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts.
Mer AS; Ba-Alawi W; Smirnov P; Wang YX; Brew B; Ortmann J; Tsao MS; Cescon DW; Goldenberg A; Haibe-Kains B
Cancer Res; 2019 Sep; 79(17):4539-4550. PubMed ID: 31142512
[TBL] [Abstract][Full Text] [Related]
10. DeepDRK: a deep learning framework for drug repurposing through kernel-based multi-omics integration.
Wang Y; Yang Y; Chen S; Wang J
Brief Bioinform; 2021 Sep; 22(5):. PubMed ID: 33822890
[TBL] [Abstract][Full Text] [Related]
11. A gentle introduction to understanding preclinical data for cancer pharmaco-omic modeling.
Piyawajanusorn C; Nguyen LC; Ghislat G; Ballester PJ
Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34368843
[TBL] [Abstract][Full Text] [Related]
12. Stepwise group sparse regression (SGSR): gene-set-based pharmacogenomic predictive models with stepwise selection of functional priors.
Jang IS; Dienstmann R; Margolin AA; Guinney J
Pac Symp Biocomput; 2015; 20():32-43. PubMed ID: 25592566
[TBL] [Abstract][Full Text] [Related]
13. Analyzing the clinical actionability of germline pharmacogenomic findings in oncology.
Wellmann R; Borden BA; Danahey K; Nanda R; Polite BN; Stadler WM; Ratain MJ; O'Donnell PH
Cancer; 2018 Jul; 124(14):3052-3065. PubMed ID: 29742281
[TBL] [Abstract][Full Text] [Related]
14. Predicting Drug Response and Synergy Using a Deep Learning Model of Human Cancer Cells.
Kuenzi BM; Park J; Fong SH; Sanchez KS; Lee J; Kreisberg JF; Ma J; Ideker T
Cancer Cell; 2020 Nov; 38(5):672-684.e6. PubMed ID: 33096023
[TBL] [Abstract][Full Text] [Related]
15. Cell-Line Selectivity Improves the Predictive Power of Pharmacogenomic Analyses and Helps Identify NADPH as Biomarker for Ferroptosis Sensitivity.
Shimada K; Hayano M; Pagano NC; Stockwell BR
Cell Chem Biol; 2016 Feb; 23(2):225-235. PubMed ID: 26853626
[TBL] [Abstract][Full Text] [Related]
16. Anticancer drug sensitivity prediction in cell lines from baseline gene expression through recursive feature selection.
Dong Z; Zhang N; Li C; Wang H; Fang Y; Wang J; Zheng X
BMC Cancer; 2015 Jun; 15():489. PubMed ID: 26121976
[TBL] [Abstract][Full Text] [Related]
17. Genetic Interactions and Tissue Specificity Modulate the Association of Mutations with Drug Response.
Cramer D; Mazur J; Espinosa O; Schlesner M; Hübschmann D; Eils R; Staub E
Mol Cancer Ther; 2020 Mar; 19(3):927-936. PubMed ID: 31826931
[TBL] [Abstract][Full Text] [Related]
18. MERIDA: a novel Boolean logic-based integer linear program for personalized cancer therapy.
Lenhof K; Gerstner N; Kehl T; Eckhart L; Schneider L; Lenhof HP
Bioinformatics; 2021 Nov; 37(21):3881-3888. PubMed ID: 34352075
[TBL] [Abstract][Full Text] [Related]
19. Large-scale pharmacogenomic studies and drug response prediction for personalized cancer medicine.
Feng F; Shen B; Mou X; Li Y; Li H
J Genet Genomics; 2021 Jul; 48(7):540-551. PubMed ID: 34023295
[TBL] [Abstract][Full Text] [Related]
20. TranSynergy: Mechanism-driven interpretable deep neural network for the synergistic prediction and pathway deconvolution of drug combinations.
Liu Q; Xie L
PLoS Comput Biol; 2021 Feb; 17(2):e1008653. PubMed ID: 33577560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
